^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PARD3 overexpression

    i
    Other names: PARD3, Par-3 Family Cell Polarity Regulator, PAR3, ASIP, PPP1R118, Bazooka, PARD3A, Baz, Atypical PKC Isotype-Specific Interacting Protein, Protein Phosphatase 1, Regulatory Subunit 118, Par-3 Family Cell Polarity Regulator Alpha, Partitioning Defective 3 Homolog, CTCL Tumor Antigen Se2-5, PAR3-Alpha, PARD-3, Par-3 (Partitioning Defective 3, C.Elegans) Homolog, Par-3 Partitioning Defective 3 Homolog (C. Elegans), Atypical PKC Isotype-Specific-Interacting Protein, Par-3 Partitioning Defective 3 Homolog, PAR3alpha, SE2-5L16, SE2-5LT1, SE2-5T2, PAR3A, PAR-3
    Entrez ID:
    56288
    Related biomarkers:
    Expression
    2years
    PARD3 drives tumorigenesis through activating Sonic Hedgehog signalling in tumour-initiating cells in liver cancer. (PubMed, J Exp Clin Cancer Res)
    This study revealed PARD3 as a potential preventive target of liver tumorigenesis via TIC regulation.
    Journal
    |
    GLI1 (GLI Family Zinc Finger 1) • SOX2 • PARD3 (Par-3 Family Cell Polarity Regulator)
    |
    CD133 expression • CD133 overexpression • PARD3 expression • PARD3 overexpression
    4years
    Polarity protein Par3 sensitizes breast cancer to paclitaxel by promoting cell cycle arrest. (PubMed, Breast Cancer Res Treat)
    Par3 facilitates polymeric forms of tubulin and stabilizes microtubule structure, which aggravates paclitaxel-induced delay at the metaphase-anaphase transition, leading to proliferation inhibition and apoptosis of breast cancer cells. Par3 has a potential role in sensitizing breast cancer cells to paclitaxel, which may provide a more precise assessment of individual treatment and novel therapeutic targets.
    Journal
    |
    PARD3 (Par-3 Family Cell Polarity Regulator)
    |
    PARD3 expression • PARD3 overexpression
    |
    paclitaxel